The team of Pierre Thibault, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) and professor in the Department of Chemistry of the Université of Montréal, in collaboration with colleagues from the University Paris-Descartes recently published in the journal Nature Communications a new proteomics approach for the global-scale analysis of protein SUMOylation with unprecedented sensitivity and depth. SUMOylation, an important type of protein modification, regulates many cellular processes such as cell division, intracellular trafficking, protein degradation and senescence. An imbalance of this modification can result in cell proliferation and the development of tumors.
Within cells, the activity of many proteins is governed by different reversible chemical modifications. Ubiquitylation and SUMOylation are two such modifications that involve the transfer of small proteins, respectively called Ubiquitin (Ub) and SUMO (Small Ubiquitin-like Modifier), to specific sites on the targeted proteins. In particular, Ub often acts as a tag that marks proteins for degradation by the proteasome, a normal and essential process. Indeed, in the cell, there is a continual turnover of proteins, which implies a permanent process of synthesis and degradation. This dynamic between synthesis and degradation ensures the quality control of proteins and allows the cell to adapt quickly to changes in its environment.
The new approach described recently allows a deeper analysis of the regulation of proteins modified by SUMOylation. The researchers found that many proteins are modified by both SUMOylation and ubiquitylation and that there is a functional crosstalk between these changes. In addition, this work revealed a new mechanism by which the proteasome undergoes strong SUMOylation during a cellular stress and this modification is necessary for its interaction with the PML nuclear bodies, an organelle associated with the degradation of some nuclear proteins. This perturbation of the interaction between the proteasome and PML nuclear bodies can lead to the proliferation of leukemic cells in acute promyelocytic leukemia.
This recent study opens new avenues for the identification of protein substrates, their specific modification sites, the interaction between SUMOylation and ubiquitylation, and their regulation in different diseases.
Frédéric Lamoliatte, Francis McManus, Ghizlane Maarifi, Mounira K. Chelbi-Alix, Pierre Thibault, Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification, Nature Communications 2017, 8:14109.
About the Institute for Research in Immunology and Cancer
An ultra-modern research hub and training centre located in the heart of the Université de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For further information
Communication and media relations advisor
Institute for Research in Immunology and Cancer│IRIC
Université de Montréal